Psychotherapy and Psychosomatics
March 18, 2019
Kurt Stocker, G. Hasler, Matthias Hartmann
5 “I kind of enjoyed the next few hours till dinner. I was still kind of floating on air” (5: 06) (T29). 6 “I had this awkward weight that I carried around me wherever I went (0: 47) ... Literally I had the sensation of this steal armor that I wore my entire life [that] – chunks of it – were falling off (3: 03)” (T16). 7 “I did immediately following the first session – and in the second and in...
bioRxiv (Cold Spring Harbor Laboratory)
March 16, 2019
Diego Quattrone, Laura Ferraro, Giada Tripoli et al.
3 citations
preprint
Abstract Objective The evidence is mixed on whether cannabis use is associated with a particular symptomatology in first episode psychosis (FEP) patients. The authors set out to investigate a) patterns of association between cannabis use and transdiagnostic symptom dimensions; b) whether the extent of use of cannabis contributes to the variation in clinical and subclinical symptom profiles....
Journal of Psychoactive Drugs
March 15, 2019
Jennifer Dore, Brent Turnipseed, Shannon Dwyer et al.
207 citations
Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as...
Journal of Psychoactive Drugs
March 15, 2019
Lisa Jerome, Brad Burge, Richard Doblin et al.
87 citations
Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of...
Proceedings of the National Academy of Sciences
March 13, 2019
Panos Zanos, Jaclyn N. Highland, Brent W. Stewart et al.
153 citations
Significance Despite available medications for depression, currently approved antidepressants take months to exert therapeutic effects, and ∼30% of patients remain treatment resistant. In contrast, a single subanesthetic dose of ketamine exerts rapid (within hours) and sustained antidepressant actions. Preclinical studies indicate that the ketamine metabolite ( 2R , 6R )-hydroxynorketamine [(...
Journal of Psychoactive Drugs
March 6, 2019
Ansgar Rougemont-Bücking, Henrik Jungaberle, Milan Scheidegger et al.
6 citations
Differences in mental health (MH) of users of distinct psychoactive substances have been shown. Both substance use (SU) and MH in users are influenced by stressful life events. This study compared MH parameters in distinct groups of substance users and evaluated the impact of stress factors on these outcomes. Data stem from the longitudinal Swiss Cohort Study on Substance Use Risk Factors...
The American Journal of Drug and Alcohol Abuse
March 4, 2019
Elias Dakwar
1 citation
This article refers to:5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
Behavioural and Cognitive Psychotherapy
March 2019
Stephanie Louise, Susan L. Rossell, Neil Thomas
A prominent area of advancement in the psychological treatment for people with persisting psychosis has been the application of mindfulness-based therapies. Recent literature has recommended the investigation of focused mindfulness interventions for voices (auditory hallucinations) as a specific experience. To date, only mindfulness programs in group format have been examined. This...
Brain and Behavior
March 2019
Luca Baldelli, Olga Addimanda, Marco Burattini et al.
To investigate the prevalence of REM sleep behavior disorder (RBD) in patients with inflammatory arthritis (IA) to ascertain if RBD could be an internal red flag signaling a fluctuating state of inflammation based on the theory of "protoconsciousness". One hundred and three patients with a confirmed diagnosis of IA were consecutively recruited. The patients underwent general (IA activity,...
American Journal of Geriatric Psychiatry
March 1, 2019
Akshya Vasudev, Michael Lifshitz, S. B. Peckham et al.
Abstract Mindfulness and transcendental meditation techniques have emerging research supporting them as positive additions to treatment as usual/standard care for mood and/or cognitive disorders among older adults. This session will highlight this recent research and evidence of the benefits of these interventions in the context of late-life depression (LLD) and late-life anxiety (LLA). In the...